Study in Subjects With Small Primary Choroidal Melanoma

Completed · Phase 1/Phase 2

Conditions studied: Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma

In brief

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Key facts

Study ID

NCT03052127

Run by

Aura Biosciences

People needed

57

Starts

2017-02-27

Expected to finish

2021-01-26

Last updated by the study team

2024-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of choroidal melanoma

You may not qualify if…

• Have known contraindications or sensitivities to the study drug

Where it is running

• Retina Associates SW, P.C. — Tucson, Arizona, United States
• UCLA Jules Stein Eye Institute — Los Angeles, California, United States
• Byers Eye Institute at Stanford University — Palo Alto, California, United States
• Retina Consultants of Sacramento — Sacramento, California, United States
• Colorado Retina Associates — Denver, Colorado, United States
• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States
• W. K. Kellogg Eye Center, University of Michigan — Ann Arbor, Michigan, United States
• Associated Retinal Consultants, PC — Royal Oak, Michigan, United States
• Retina Center — Minneapolis, Minnesota, United States
• Columbia University Medical Center — New York, New York, United States
• Wills Eye Hospital — Philadelphia, Pennsylvania, United States
• Retina Consultants of Carolina, PA — Greenville, South Carolina, United States
• Retina Consultants of Houston — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.